A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:79
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [11] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
    Zi-cheng Yu
    Pei-jun Zhou
    Xiang-hui Wang
    Bressolle Françoise
    Da Xu
    Wei-xia Zhang
    Bing Chen
    Acta Pharmacologica Sinica, 2017, 38 : 1566 - 1579
  • [12] Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients
    Tornatore, Kathleen M.
    Sudchada, Patcharaporn
    Dole, Kiran
    DiFrancesco, Robin
    Leca, Nicolae
    Gundroo, Aijaz C.
    Danison, Ryan T.
    Attwood, Kris
    Wilding, Gregory E.
    Zack, Julia
    Forrest, Alan
    Venuto, Rocco C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (08) : 1213 - 1222
  • [13] Variability of mycophenolic acid elimination in the renal transplant recipients - population pharmacokinetic approach
    Velickovic-Radovanovic, Radmila M.
    Jankovic, Slobodan M.
    Milovanovic, Jasmina R.
    Catic-Dordevic, Aleksandra K.
    Spasic, Ana A.
    Stefanovic, Nikola Z.
    Dzodic, Predrag Lj.
    Smelcerovic, Andrija A.
    Cvetkovic, Tatjana P.
    RENAL FAILURE, 2015, 37 (04) : 652 - 658
  • [14] Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients - Comparison of cyclosporin and tacrolimus treatment
    Wada, Kyoichi
    Takada, Mitsutaka
    Kotake, Takeshi
    Ochi, Hiroyuki
    Morishita, Hideki
    Komamura, Kazuo
    Oda, Noboru
    Mano, Akiko
    Kato, Tomoko
    Hanatani, Akihisa
    Nakatani, Takeshi
    CIRCULATION JOURNAL, 2007, 71 (07) : 1022 - 1028
  • [15] Analysis of urinary donor-derived DNA in renal transplant recipients with acute rejection
    Zhang, ZH
    Ohkohchi, N
    Sakurada, M
    Mizuno, Y
    Miyagi, S
    Satomi, S
    Yamaguchi, M
    Okazaki, H
    CLINICAL TRANSPLANTATION, 2002, 16 : 45 - 50
  • [16] No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients
    Kagaya, H.
    Miura, M.
    Satoh, S.
    Inoue, K.
    Saito, M.
    Inoue, T.
    Habuchi, T.
    Suzuki, T.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (02) : 193 - 201
  • [17] Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients
    Colom, Helena
    Lloberas, Nuria
    Andreu, Franc
    Caldes, Ana
    Torras, Joan
    Oppenheimer, Federico
    Sanchez-Plumed, Jaime
    Gentil, Miguel A.
    Kuypers, Dirk R.
    Brunet, Merce
    Ekberg, Henrik
    Grinyo, Josep M.
    KIDNEY INTERNATIONAL, 2014, 85 (06) : 1434 - 1443
  • [18] Evaluation of Mycophenolic Acid Exposure Using a Limited Sampling Strategy in Renal Transplant Recipients
    Li, Jun
    Liu, Yanfeng
    Huang, Jiawen
    Fu, Qian
    Chen, E.
    Liu, Longshan
    Zhang, Rui
    Huang, Min
    Wang, Changxi
    AMERICAN JOURNAL OF NEPHROLOGY, 2013, 37 (06) : 534 - 540
  • [19] Race and Drug Formulation Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
    Tornatore, Kathleen M.
    Sudchada, Patcharaporn
    Attwood, Kris
    Wilding, Gregory E.
    Gundroo, Aijaz C.
    DiFrancesco, Robin
    Gray, Vanessa
    Venuto, Rocco C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03) : 285 - 293
  • [20] Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
    Atcheson, BA
    Taylor, PJ
    Kirkpatrick, CMJ
    Duffull, SB
    Mudge, DW
    Pillans, PI
    Johnson, DW
    Tett, SE
    THERAPEUTIC DRUG MONITORING, 2004, 26 (03) : 284 - 286